Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insulet Corp PODD

Healthcare Medical Devices
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, the Omnipod Insulin Management System, and Omnipod GO. It also... see more

Recent & Breaking News (NDAQ:PODD)

Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023

Business Wire July 5, 2023

Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions

Business Wire June 22, 2023

Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom

Business Wire June 20, 2023

Insulet Announces New Organizational Structure to Drive Further Growth

Business Wire May 4, 2023

Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)

Business Wire May 4, 2023

Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment

Business Wire May 2, 2023

Insulet Announces FDA Clearance of Omnipod GO(TM), a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

Business Wire April 25, 2023

Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023

Business Wire March 30, 2023

Insulet Set to Join S&P 500

PR Newswire March 10, 2023

Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)

Business Wire February 23, 2023

Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Business Wire February 21, 2023

Insulet to Present at Upcoming Investor Conferences

Business Wire February 14, 2023

Insulet Acquires Assets of Automated Glucose Control LLC (AGC)

Business Wire February 14, 2023

Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery Technologies

Business Wire February 13, 2023

Insulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Business Wire January 12, 2023

Insulet to Present at Upcoming Investor Conferences

Business Wire November 22, 2022

Insulet Issues a Nationwide Voluntary Medical Device Correction for the Omnipod® 5 Controller

Business Wire November 14, 2022

Insulet Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Business Wire November 4, 2022

Insulet Reports Third Quarter 2022 Revenue Increase of 24% Year-Over-Year (29% Constant Currency1)

Business Wire November 3, 2022

Insulet Recognizes World Diabetes Day and Diabetes Awareness Month Throughout November

Business Wire November 1, 2022